Introduction
Hypothermia has been widely used by several biomedical disciplines, and recognized as an effective cytoprotectant. It has been studied to improve outcome from myocardial infarction (Holzer and Behringer, 2008; Schefold et al., 2008) , organ transplantation (El-Wahsh, 2007; Anaya-Prado and DelgadoVazquez, 2008) , cardiopulmonary bypass (Drinkwater and Laks, 1993) , spinal cord injury (SCI) (Yoshitake et al., 2007) , intestinal ischemia (Stefanutti et al., 2008) , and neonatal hypoxia-ischemia (Wagner et al., 2002; Mishima et al., 2004; Zhu et al., 2004; Edwards and Azzopardi, 2006) . At the clinical level, it has been shown from a small number of prospective randomized studies to improve neurological outcome from cardiac arrest (Bernard et al., 2002; HACA, 2002) and neonatal hypoxia-ischemia (Gluckman et al., 2005; Shankaran et al., 2005) .
A physiological example of hypothermia can be observed in species that normally hibernate. In these animals, body temperature and metabolism drops in a manner reminiscent of that observed when intentional hypothermia is applied (Johansson, 1996; Drew et al., 2001; Nathaniel, 2008) . In fact, these parallels have led some investigators to wonder if human hibernation is possible (Lee, 2008) . Hypothermia has once been thought to be the ''gold standard'' to which the other laboratory studies investigation cytoprotection should be compared (Krieger and Yenari, 2004) .
Hypothermia can be classified based on the depth of cooling from a normal body temperature of 37-38 8C: mild hypothermia (32-35 8C), moderate hypothermia (28-32 8C) and deep hypothermia (<28 8C). While deep hypothermia has been embraced by various surgical subspecialties, the neuroprotective effect of mild to moderate hypothermia appears to be similar to deep (Huh et al., 2000) . Thus, less drastic decreases in body temperature have been favored by other disciplines, as it is easier to cool nonsurgical patients to these target temperatures, and the risks of medical complications such as infection, arrhythmia, hypokalemia, coagulopathies and even heart failure in older patients are lower.
There are many mechanisms by which hypothermia may be cytoprotective. Earlier literature has focused on its ability to preserve metabolic stores and thus render the tissue or organism in a state of ''suspended animation' ' (Bellamy et al., 1996) . Hypothermia has generally been viewed as a means by which protein synthesis can be suppressed. However, the widely held notion that hypothermia protects because lower temperatures slow metabolism is not completely accurate (Yenari et al., 2004) . Recent research has shown that hypothermia can alter a plethora of cell death and cell survival pathways including gene regulation resulting in the inhibition of apoptosis and inflammation (Han and Yenari, 2005; Liu and Yenari, 2007) Hypothermia is a well established cytoprotectant, with remarkable and consistent effects demonstrated across multiple laboratories. At the clinical level, it has recently been shown to improve neurological outcome following cardiac arrest and neonatal hypoxia-ischemia. It is increasingly being embraced by the medical community, and could be considered an effective neuroprotectant. Conditions such as brain injury, hepatic encephalopathy and cardiopulmonary bypass seem to benefit from this intervention. It's role in direct myocardial protection is also being explored. A review of the literature has demonstrated that in order to appreciate the maximum benefits of hypothermia, cooling needs to begin soon after the insult, and maintained for relatively long period periods of time. In the case of ischemic stroke, cooling should ideally be applied in conjunction with the re-establishment of cerebral perfusion. Translating this to the clinical arena can be challenging, given the technical challenges of rapidly and stably cooling patients. This review will discuss the application of hypothermia especially as it pertains to its effects neurological outcome, cooling methods, and important parameters in optimizing hypothermic protection.
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